Spawning success

More than a decade after DNA vaccines emerged as a novel therapeutic genre, two such products have received marketing approval just days apart, albeit for disease prevention in horses and salmon. Vical Inc., which out-licensed the salmon product, believes the approval validates its technology and is looking to build on its argument with a Phase II proof-of-concept trial of a bivalent vaccine to treat cytomegalovirus infection

Read the full 669 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE